Lorundrostat demonstrated a favorable safety and tolerability profile in the Launch-HTN trial, noting that while hyponatremia, hyperkalemia, and reduced kidney function occurred more frequently in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback